共 18 条
[1]
Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes, Clinical Pharmacology and Therapeutics, 40, (1990)
[2]
A report of the Post-marketing Surveillance Working Party, Post-marketing Surveillance Quadripartite Guidelines, (1991)
[3]
WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up, Lancet, 1, pp. 379-385, (1980)
[4]
Corstjens M., Marketing strategy in the pharmaceutical industry, (1991)
[5]
Faich G.A., Postmarketing surveillance: lessons learned, Drug Information Journal, 25, pp. 531-535, (1991)
[6]
Faich G.A., Guess H.A., Kuritsky J.M., Postmarketing surveillance for drug safety, Clinical trials and tribulations, (1988)
[7]
Gordon A.J., Petrick R.J., Worldwide regulations for manufacturers on clinical safety surveillance of drugs, Drug Information Journal, 26, pp. 1-15, (1992)
[8]
Inman W.H.W., PEM 2000, Drug Safety Research Unit PEM News, 7, (1991)
[9]
Guidelines on postmarketing surveillance, British Medical Journal, 296, pp. 399-400, (1988)
[10]
Petri H., Urquhart J., Channeling bias in the interpretation of drug effects, Statistics in Medicine, 10, pp. 577-582, (1991)